Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)’s share price traded down 5.4% during trading on Monday . The company traded as low as $13.62 and last traded at $14.36, 724,067 shares traded hands during mid-day trading. An increase of 59% from the average session volume of 456,704 shares. The stock had previously closed at $15.18.
A number of equities analysts have recently commented on the company. ValuEngine downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 22nd. BidaskClub upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Citigroup raised their price objective on Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Finally, Chardan Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Dicerna Pharmaceuticals in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.57.
The business has a 50 day simple moving average of $14.21 and a two-hundred day simple moving average of $13.90. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -11.97 and a beta of 2.23.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $5.68 million for the quarter, compared to analyst estimates of $10.95 million. Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. Research analysts anticipate that Dicerna Pharmaceuticals Inc will post -1.31 EPS for the current fiscal year.
In related news, insider James B. Weissman sold 14,680 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total value of $191,867.60. Following the sale, the insider now owns 9,800 shares of the company’s stock, valued at approximately $128,086. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 21.28% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in DRNA. Quantamental Technologies LLC raised its stake in Dicerna Pharmaceuticals by 94.4% during the 2nd quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,700 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Dicerna Pharmaceuticals during the 2nd quarter valued at $68,000. Bank of America Corp DE increased its position in shares of Dicerna Pharmaceuticals by 30.3% during the 4th quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 2,465 shares during the period. Athanor Capital LP acquired a new position in shares of Dicerna Pharmaceuticals during the 2nd quarter valued at $233,000. Finally, Marshall Wace North America L.P. increased its position in shares of Dicerna Pharmaceuticals by 261.6% during the 1st quarter. Marshall Wace North America L.P. now owns 17,886 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 12,939 shares during the period. 82.04% of the stock is currently owned by institutional investors and hedge funds.
About Dicerna Pharmaceuticals (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: How does a security become overbought?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.